Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score

International Journal of Cardiology
Josep LupónAntoni Bayes-Genis

Abstract

Limited data exists regarding biomarker use to predict left ventricular (LV) reverse remodeling (R2). Our aim was to examine the value of soluble ST2 (ST2), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and galectin-3 relative to LV-R2 in systolic heart failure (HF), and to develop a clinical score for LV-R2 prediction. R2 was defined as a) LV ejection fraction (LVEF) increase ≥15%, or b) LVEF increase ≥10% plus reduction of LV end-systolic diameter index ≥20% or LV end-systolic volume ≥40%, for 12 months. We studied 304 patients (79.6% men, mean age 66.1 ± 12.3 years) with baseline LVEF <40%. R2 was observed in 104 patients (34.2%). In univariable logistic regression, factors associated with R2 were age (p=0.02), non-ischemic etiology of HF (p<0.001), NYHA functional class (p=0.02), baseline LVEF (p=0.005), absence of left bundle branch block (LBBB; p=0.002), ST2 (p=0.004), NT-proBNP (p=0.005), and hs-cTnT (p<0.001); HF duration achieved borderline significance (p=0.08). In multivariable analysis, ST2 remained the only biomarker associated with LV-R2. We developed the ST2-R2 score for use in clinical practice for predicting R2; variables included were ST2 <48 ng/mL, non-i...Continue Reading

References

Dec 12, 2001·Journal of the American College of Cardiology·J LindenfeldUNKNOWN MOCHA (Multicenter Oral Carvedilol Heart failure Assessment) Investigators
Jul 19, 2002·The New England Journal of Medicine·Alan S MaiselUNKNOWN Breathing Not Properly Multinational Study Investigators
Jun 18, 2004·Heart·N G BellengerUNKNOWN CHRISTMAS Study Steering Committee and Investigators
May 12, 2007·The Journal of Clinical Investigation·Shoji SanadaRichard T Lee
Aug 13, 2008·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Charles DelagardelleDaniel R Wagner
Mar 24, 2010·Archives of Internal Medicine·Pramote PorapakkhamHenry Krum
Jan 15, 2011·JACC. Cardiovascular Imaging·Marvin A KonstamJames E Udelson
Mar 1, 2012·Circulation. Heart Failure·Bonnie KyThomas P Cappola
Apr 10, 2012·The American Journal of Cardiology·Marie FertinChristophe Bauters
Apr 6, 2013·Journal of Cardiovascular Translational Research·James L Januzzi
Jun 7, 2013·Circulation·UNKNOWN WRITING COMMITTEE MEMBERSUNKNOWN American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

❮ Previous
Next ❯

Citations

Apr 2, 2015·International Journal of Cardiology·Kenan Yalta
Apr 10, 2016·International Journal of Cardiology·Kenan YaltaErtan Yetkin
Oct 21, 2016·Current Heart Failure Reports·Shweta R Motiwala, Hanna K Gaggin
Mar 8, 2018·Heart Failure Reviews·Michele CorrealeUNKNOWN Master Program Students on Drug Development for Heart Failure
Oct 9, 2018·Expert Review of Cardiovascular Therapy·Marco MasèGianfranco Sinagra
Feb 6, 2020·BioMed Research International·Xi-Ying WangJian Yang
Dec 26, 2016·The International Journal of Cardiovascular Imaging·Sandra AmorimM Júlia Maciel
Oct 26, 2018·Hypertension·Rana GhaliGeorge W Booz
Jan 23, 2021·Current Heart Failure Reports·Andrew Abboud, James L Januzzi
Feb 22, 2021·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Mahnaz SalmaniHossein Imani
May 19, 2021·ESC Heart Failure·Kaiming WangGavin Y Oudit

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.